The UK Myeloma Forum (UKMF) is a collaborative organisation of healthcare professionals and scientists which aims to improve the treatment of patients with myeloma. The annual UKMF Scientific Workshop is an all-day event where leading experts share the latest biomedical research aiming to improve understanding of myeloma and develop new strategies to improve patient outcomes. This year’s…
Myeloma is a relapsing-remitting blood cancer arising from the clonal expansion of abnormal plasma cells in the bone marrow. It is a difficult cancer to diagnose due to the vagueness of symptoms and rarity of the disease. This means myeloma patients experience some of the longest delays in diagnosis of all cancer patients. Myeloma UK…
This new treatment combination is being made available via the CDF on the NHS for the first time following a recommendation by the National Institute of Health and Care Excellence (NICE). This decision follows an earlier draft negative decision by NICE in July last year. Daratumumab, which is produced by the pharmaceutical company Janssen, belongs to a…
The IMWG present updated recommendations for the treatment of vertebral compression fractures in patients with myeloma by cement augmentation
As whole-body MRI is listed in NICE guidance as the recommended first line imaging in patients with suspected myeloma, this paper outlines a clinical protocol: the Myeloma Response Assessment and Diagnosis System (MY-RADS), for its use and interpretation.
Common Terminology Criteria for Adverse Events (CTCAE) is widely accepted as the standard classification and severity grading scale for adverse events in cancer therapy, clinical trials and other oncology settings. Version 5.0 is the most updated document (November 27, 2017)
The European Myeloma Network have published recommendations on diagnostic, prognostic and monitoring tests for patients with myeloma.
The European Myeloma Network have published recommendations on diagnostic, prognostic and monitoring tests for patients with myeloma.
These guidelines, produced by the National Institute for Health and Care Excellence (NICE), set out new recommendations for the diagnosis, treatment and care of myeloma patients with the aim of providing consistently excellent patient-focused care within the NHS in England. Update information October 2018: Recommendations 1.8.13 to 1.8.17 were replaced by NICE’s guideline on venous thromboembolism in…
